[1] Simon TG, Wilechansky RM, Stoyanova S, et al.Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: A randomized clinical trial.JAMA, 2024,331(11):920-929. [2] Feng G, Valenti L, Wong VW, et al.Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol, 2024,21(1):46-56. [3] 黄洁杰,郑倩,等.利拉鲁肽联合阿托伐他汀钙治疗伴有糖脂代谢异常的非酒精性脂肪性肝病患者疗效研究.实用肝脏病杂志,2024,27(1):36-39. [4] 刘亚杰,王睿林.胰岛素抵抗指数与非酒精性脂肪性肝病的相关性研究.中国临床研究,2024,37(9):1398-1402,e1407. [5] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4):494-510. [6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊断标准.中华肝脏病杂志,2003,11(2):71. [7] Grander C, Grabherr F, Tilg H.Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.Cardiovasc Res, 2023,119(9): 1787-1798. [8] RigorJ,Diegues A, Presa J,et al.Noninvasive fibrosis tools in NAFLD:validatiOn Of APRI,BARD,FlB-4,NAFLD fibrosis score,and Hepamet fibrosis score in a Portuguese population.Postgrad Med,2022,134(4):435-440. [9] 卢蓉,李慧,张超,等.甘油三酯/葡萄糖指数预测非酒精性脂肪性肝病严重程度效能研究.实用肝脏病杂志,2023,26(6):805-810. [10] Man S,Deng Y,Ma Y,etal.Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China.Gastroenterology,2023,165(4):1025-1040. [11] Mayneris-Perxachs J,Cardellini M,Hoyles L,et al.Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome.Microbiome,2021,9(1):104. [12] 孙丽娜,顾静.非酒精性脂肪性肝病合并2型糖尿病患者血清铁蛋白变化及其临床意义.实用肝脏病杂志,2021,24(2):294-296. [13] 黄绮堂,李延莉.铁代谢异常与淋巴造血系统肿瘤的研究进展.中国实验血液学杂志,2022,30(4):1277-1280. [14] HiltonC,Sabaratnam R,Drakesmith H,et al.Iron, glucose and fat metabolism and obesity: an intertwined relationship.Int J Obes (Lond),2023,47(7):554-563. [15] Rochette L,Dogon G,Rigal E,et al.Lipid peroxidation and iron metabolism: Two corner stones in the homeostasiscontrol of ferroptosis.Int J Mol Sci,2022,24(1):449. [16] Rho H,Terry AR,Chronis C,et al.Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis.Cell Metab,2023,35(8):1406-1423,e8. [17] Nassir F.NAFLD: Mechanisms, treatments, and biomarkers.Biomolecules,2022,12(6):824. [18] Xu S,Wu X,Wang S,et al.TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase.J Clin Invest,2024,134(5):e166149. [19] Kim HK,BaeSJ,Lee MJ, et al. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity.Clin Mol Hepatol,2023,29(4):987-1001. [20] 刘虎,赵宏伟.基于MRI技术的血液透析患者肝脏铁过载和肝脂肪变性评估:现状、挑战与展望.中国医学科学院学报,2024,46(3):449-457. |